Fortress Biotech, Inc. Accrued Salaries, Current
Fortress Biotech, Inc. (FBIO) had Accrued Salaries, Current of $7.33 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedSalariesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Salaries, Current $7.33M.
- 2026-03-31: Accrued Salaries, Current $7.38M.
- 2025-12-31: Accrued Salaries, Current $7.88M.
- 2025-09-30: Accrued Salaries, Current $7.27M.
| Period end | Accrued Salaries, Current |
|---|---|
| 2026-06-30 | $7.33M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $7.38M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $7.88M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $7.27M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $4.69M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $6.11M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $6.60M 10-K · filed 2026-03-31 |
| 2024-09-30 | $6.06M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $4.90M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $6.59M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $8.53M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.59M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $6.81M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $8.41M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $9.77M 10-K · filed 2024-03-28 |
| 2022-09-30 | $8.88M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $7.51M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $9.06M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.81M 10-K · filed 2023-03-31 |
| 2021-09-30 | $7.10M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $5.21M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $5.98M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $6.70M 10-K · filed 2022-03-28 |
| 2020-09-30 | $5.68M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $4.06M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $6.14M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $6.68M 10-K/A · filed 2021-04-09 |
| 2019-09-30 | $5.86M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $4.48M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $5.59M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $5.84M 10-K · filed 2020-03-16 |
| 2018-09-30 | $4.35M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $3.57M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $6.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $5.28M 10-K · filed 2019-03-18 |
| 2017-09-30 | $4.18M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $2.29M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $3.53M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $2.85M 10-K · filed 2018-03-16 |
| 2016-09-30 | $1.78M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $1.57M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $762.00K 10-Q · filed 2016-05-10 |
| 2015-12-31 | $2.49M 10-K · filed 2017-03-16 |
| 2015-09-30 | $961.00K 10-Q · filed 2015-11-09 |
| 2015-06-30 | $640.00K 10-Q · filed 2015-08-10 |
| 2015-03-31 | $376.00K 10-Q · filed 2015-05-11 |
| 2014-12-31 | $598.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | $632.00K 10-Q · filed 2014-11-06 |
| 2014-06-30 | $430.00K 10-Q · filed 2014-08-11 |
| 2014-03-31 | $272.00K 10-Q · filed 2014-05-12 |
| 2013-12-31 | $450.00K 10-K · filed 2015-03-16 |
| 2013-09-30 | $582.00K 10-Q · filed 2013-11-01 |
| 2013-06-30 | $739.00K 10-Q · filed 2013-08-05 |
| 2013-03-31 | $575.00K 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.06M 10-K · filed 2014-03-14 |
| 2012-09-30 | $756.00K 10-Q · filed 2012-11-14 |
| 2012-06-30 | $640.00K 10-Q · filed 2012-08-08 |
| 2011-12-31 | $493.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |